Overview

Self Titration With Apidra to Reach Target Study (START)

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective: The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at breakfast in Canadian patients with inadequately controlled T2DM after optimization of basal insulin, compared with an HCP-managed titration algorithm. The primary endpoint for assessment of this objective is the percent of patients reaching a target HbA1c <=7.0% without severe hypoglycemia at the end of the study. Secondary Objective: Secondary objectives of the study are to compare the effect of the two different insulin glulisine titration algorithms (patient-managed versus HCP-managed) on the following: - change in HbA1c, FG, and 7-point glucose profile at Week 24 and Week 36 - satisfaction with treatment (DTSQc for patient and questionnaire for HCP) at Week 36 - change in weight at Week 24 and Week 36 - incidence of hypoglycemia - insulin doses - resource utilization (rural/urban, blood glucose meter test strips, lancets, HCP visits, telephone calls, and hospitalizations) - adherence with the patient-managed monitoring algorithm
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc